source
- Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…
- Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trialArgenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…